

1 **PMRT1, a *Plasmodium* specific parasite plasma membrane transporter is essential for asexual** 2 **and sexual blood stage development**

3

4 Jan Stephan Wichers^{1,2,3}, Paolo Mesén-Ramírez², Gwendolin Fuchs^{1,2,3}, Jing Yu-Strzelczyk⁴,
5 Jan Stäcker², Heidrun von Thien^{1,2}, Arne Alder^{1,2,3}, Isabelle Henshall⁵, Benjamin Liffner⁵,
6 Georg Nagel⁴, Christian Löw^{1,6}, Danny Wilson^{5,7}, Tobias Spielmann², Shiqiang Gao⁴, Tim-
7 Wolf Gilberger^{1,2,3,#}, Anna Bachmann^{1,2,3,&}, Jan Strauss^{1,2,3,6,#,&,†}

8

9 ¹Centre for Structural Systems Biology, 22607 Hamburg, Germany.

10 ²Bernhard Nocht Institute for Tropical Medicine, 20359 Hamburg, Germany.

11 ³Biology Department, University of Hamburg, 20146, Hamburg, Germany

12 ⁴Institute of Physiology, Department of Neurophysiology, Biocenter, University of Wuerzburg,
13 97070 Würzburg, Germany

14 ⁵Research Centre for Infectious Diseases, School of Biological Sciences, University of
15 Adelaide, Adelaide 5005, Australia.

16 ⁶European Molecular Biology Laboratory, Hamburg Unit, Hamburg, Germany

17 ⁷Burnet Institute, 85 Commercial Road, Melbourne 3004, Victoria, Australia.

18

19 [#]Corresponding authors: gilberger@bnitm.de, jan.strauss@geomar.de

20 [&]Contributed equally

21 [†]Present address: GEOMAR Helmholtz Centre for Ocean Research Kiel, 24105 Kiel,
22 Germany

23

24 ORCID:

25 Jan Stephan Wichers:	0000-0002-0599-1742
26 Paolo Mesén-Ramírez:	0000-0001-7842-5867
27 Jing Yu-Strzelczyk:	0000-0002-7576-6831
28 Gwendolin Fuchs:	0000-0001-9294-6984
29 Jan Stäcker:	0000-0002-4738-6639
30 Arne Alder:	0000-0003-4918-4640
31 Isabelle Henshall:	0000-0002-5906-0687
32 Benjamin Liffner:	0000-0002-1573-6139
33 Danny Wilson:	0000-0002-5073-1405
34 Georg Nagel:	0000-0001-8174-8712
35 Christian Löw:	0000-0003-0764-7483
36 Tobias Spielmann:	0000-0002-3968-4601
37 Shiqiang Gao:	0000-0001-6190-9443
38 Tim-Wolf Gilberger:	0000-0002-7965-8272
39 Anna Bachmann:	0000-0001-8397-7308
40 Jan Strauss:	0000-0002-6208-791X

41

42

43 Abstract

44 Membrane transport proteins perform crucial roles in cell physiology. The obligate intracellu-
 45 lar parasite *Plasmodium falciparum*, an agent of human malaria, relies on membrane
 46 transport proteins for the uptake of nutrients from the host, disposal of metabolic waste, ex-
 47 change of metabolites between organelles and generation and maintenance of
 48 transmembrane electrochemical gradients for its growth and replication within human eryth-
 49 rocytes. Despite their importance for *Plasmodium* cellular physiology, the functional roles of a
 50 number of membrane transport proteins remain unclear, which is particularly true for orphan
 51 membrane transporters that have no or limited sequence homology to transporter proteins in
 52 other evolutionary lineages. Therefore, in the current study, we applied endogenous tagging,
 53 targeted gene disruption, conditional knockdown and knockout approaches to investigate the
 54 subcellular localization and essentiality of six membrane transporters during intraerythrocytic
 55 development of *P. falciparum* parasites. They are localized at different subcellular structures
 56 – the food vacuole, the apicoplast, and the parasite plasma membrane – and four out of the
 57 six membrane transporters are essential during asexual development. Additionally, the
 58 plasma membrane resident transporter 1 (PMRT1, PF3D7_1135300), a unique *Plasmodium*-
 59 specific plasma membrane transporter, was shown to be essential for gametocytogenesis
 60 and functionally conserved within the genus *Plasmodium*. Overall, we reveal the importance
 61 of four orphan transporters to blood stage *P. falciparum* development, which have diverse
 62 intracellular localizations and putative functions.

63 Importance (150 words)

64 *Plasmodium falciparum*-infected erythrocytes possess multiple compartments with designat-
 65 ed membranes. Transporter proteins embedded in these membranes do not only facilitate
 66 movement of nutrients, metabolites and other molecules between these compartments, but
 67 are common therapeutic targets and can also confer antimalarial drug resistance. Orphan
 68 membrane transporter in *P. falciparum* without sequence homology to transporters in other
 69 evolutionary lineages and divergent to host transporters may constitute attractive targets for
 70 novel intervention approaches. Here, we localized six of these putative transporters at differ-
 71 ent subcellular compartments and probed into their importance during asexual parasite
 72 growth using reverse genetic approaches. In total, only two candidates turned out to be dis-
 73 pensable for the parasite, highlighting four candidates as putative targets for therapeutic in-
 74 terventions. This study reveals the importance of several orphan transporters to blood stage
 75 *P. falciparum* development.

76 Introduction

77 *Plasmodium* spp. malaria parasites inhabit diverse intracellular niches and need to import
 78 nutrients and export waste across both, host-cell and parasite membranes. Despite this,

there are less than 150 putative membrane transporters encoded in the genome of *Plasmodium falciparum*, the most virulent malaria parasite, making up only 2.5% of all encoded genes (*P. falciparum* 3D7 v3.2: 5280 genes) (1–8), which is reduced compared to other unicellular organisms of similar genome size. The loss of redundant transporters is a typical feature of many intracellular parasites (9) and, as a result, the proportion of transporters that are indispensable for parasite survival increases (2), some of which have been shown to be critical for the uptake of several anti-Plasmodial compounds and/or to be involved in drug resistance (10–23). Moreover, the parasite’s intracellular lifestyle resulted in the evolution of additional specialized transporters without human homologues (1). During its intraerythrocytic development, the parasite relies on the uptake of nutrients, such as amino acids, pantothenate or fatty acids, from its host erythrocyte as well as from the extracellular blood plasma (24–27). As *P. falciparum* resides in a parasitophorous vacuole (PV) in the host erythrocyte, nutrients acquired from the extracellular milieu must traverse multiple membranes: the erythrocyte plasma membrane (EPM), the parasitophorous vacuole membrane (PVM), the parasite plasma membrane (PPM) and eventually membranes of intracellular organelles, such as those of the apicoplast or mitochondria (24, 28–30). The unique requirements of malaria parasite survival have led to the evolution of a number of orphan transporters, whose localization or function cannot be predicted based on sequence homology to transporters in other organisms (4, 31). Despite the likely importance of uniquely adapted transporters to *P. falciparum* survival, subcellular localization, essentiality, function and substrate specificity for most *P. falciparum* transporters has not been directly determined (2, 24, 29). The best functional evidence available for many *Plasmodium*-specific transporters comes from a recent knockout screen of these orphan transporters in the rodent malaria parasite *Plasmodium berghei* (31). However, whether observations for different transporters in the *P. berghei* model are directly transferrable to *P. falciparum* have yet to be examined. Therefore, in this study, we explored the localization and essentiality of four predicted orphan transporters that had been partially characterised in *P. berghei* and included two additional transporters with no experimental characterization available.

Results

To date, the predicted ‘transportome’ of *P. falciparum* consists of 117 putative transport systems (encoded by 144 genes) classified as channels (n=19), carriers (n=69), and pumps (n=29) (2). Functions of the vast majority of transporter genes were inferred from sequence homology to model organisms, however, given their lack of homology, 39 gene products could not be associated with any functional or subcellular localization and were categorized as orphan transporters accordingly (4). A subset of orphan transporters characterized in the *P. berghei* malaria model was selected for further characterization in *P. falciparum*. The four transporters selected were reported to be important at different stages of rodent malaria par-

asite growth with i) *P. berghei* drug/metabolite transporter 2 (*PfDMT2*: PF3D7_0716900) found to be essential for asexual blood stage development, ii) *P. berghei* zinc transporter 1 (*PfZIP1*: PF3D7_0609100) was essential across transmission stages but not blood stages, where there was only a slight growth defect, iii) *P. berghei* cation diffusion facilitator family protein (*PfCDF*: PF3D7_0715900) knockout parasites had a defect during transmission stages but not during asexual stages, and iv) *P. berghei* major facilitator superfamily domain-containing protein (*PfMFS6*: PF3D7_1440800) was found to be essential for parasite transmission from mosquitos to a new host, with a growth defect observed at asexual and gametocyte stages but not during mosquito stage parasite growth (31, 32). In order to confirm expression of these four, initially selected, transporters in *P. falciparum* asexual stages, we searched the list of “Genes coding for transport proteins” included in the Malaria Parasite Metabolic Pathways (MPMP) database (1, 33) for proteins with i) RNA-seq (34, 35) and ii) proteomics evidence (36, 37) in asexual blood stages. During our initial searches of the MPMP database but also including PlasmoDB (38) and the most recent *P. falciparum* 3D7 genome (v3.2) and annotations, we identified two additional putative transporters in *P. falciparum* (PF3D7_0523800, PF3D7_1135300), whose *P. berghei* homologs were not targeted and functionally characterized by Kenthirapalan *et al.* (31) or investigated in any other experimental model. Given their obvious lack of sequence homology to transporter proteins in other evolutionary lineages and clear classification as orphan membrane transporter, both proteins were subsequently included in our characterization of *P. falciparum* orphan transporters, and named as ‘food vacuole resident transporter 1’ (FVRT1: PF3D7_0523800) and as ‘plasma membrane resident transporter 1’ (PMRT1: PF3D7_1135300) based on their subcellular localization. AlphaFold-based structure predictions (39) and results from structure homology search (40) of all six selected transporters are provided in Figure S1.

Localization of putative *P. falciparum* transporters

To determine subcellular localization, we tagged the six putative transporters endogenously with GFP using the selection-linked integration (SLI) system (41) (Figure 1A). Additionally, a glmS ribozyme sequence was included in the 3'UTR, which enabled conditional gene knock-down upon addition of glucosamine (42). Correct integration of the plasmid into the respective genomic locus was verified by PCR and expression of the GFP-fusion protein was confirmed by Western blot for each generated cell line (Figure S2A, B).

All transgenic cell lines expressed the GFP-fusion protein, demonstrating that these transporters are expressed in asexual blood stage parasites (Figure 1B-G, S2A). Expression levels were sufficient to allow determination of subcellular localization (Figure 1B-G): (i) PF3D7_0523800-GFP localized to the food vacuole, (ii) *PfDMT2*-GFP and *PfMFS6*-GFP apicoplast localization, and (iii) *PfZIP1*-GFP and PF3D7_1135300-GFP parasite plasma membrane (PPM) localization. However, *PfCDF*-GFP showed an obscure staining pattern

with a weak spot within the parasite cytosol in ring and trophozoite stage parasites, but multiple foci in schizont stages (Figure 1D). To pinpoint this localization, an additional cell line with endogenously 3xHA-tagged *PfCDF* was generated, confirming the focal localization of *PfCDF* in asexual stages (Figure S2C).

Except for *PfCDF*, the observed localizations of the other five transporters were confirmed by co-localization studies using appropriately expressed marker proteins: P40PX-mCherry (43, 44) for the food vacuole, ACP-mCherry (45, 46) for apicoplast and Lyn-mCherry (41, 47) for PPM. The focal distribution of *PfCDF*-GFP was co-localized with a rhoptry (ARO-mCherry (48, 49)) and a micronemes (AMA1-mCherry (50, 51)) marker, but *PfCDF*-GFP did not colocalize with either marker (Figure 1H). Additionally, for *PfZIP* and PF3D7_1135300 the PPM localization was further confirmed in free merozoites (Figure S2D, E) and by confocal microscopy-based co-localization of PF3D7_1135300-GFP with the PPM marker Lyn-mCherry (Figure S2F). Accordingly, as noted above, we named PF3D7_0523800 as 'food vacuole resident transporter 1' (FVRT1) and PF3D7_1135300 as 'plasma membrane resident transporter 1' (PMRT1).

Targeted-gene disruption (TGD), conditional knockdown and conditional knockout of putative transporters

In order to test whether the putative transporters are essential for *P. falciparum* during its intraerythrocytic cycle, we first tried to functionally inactivate them by targeted gene disruption (TGD) using the SLI system (41) (Figure S3A). TGD cell lines were successfully obtained for *PfZIP1* and *PfCDF* (Figure S3B, C). For *PfZIP1*-TGD, the correct integration of the plasmid into the genomic locus and absence of wildtype locus was verified by PCR and subsequent growth experiments revealed no growth defect compared to *P. falciparum* 3D7 wildtype parasites (Figure S2B), suggesting its redundancy during asexual parasite proliferation. For *PfCDF*-TGD the correct integration of the plasmid into the genomic locus was also verified, but wildtype DNA was still detectable and remained even upon prolonged culturing under G418/WR selection and limited dilution cloning (Figure S3C). In contrast, six (*PfPMRT1*, *PfDMT2*) or eight (*PfFVRT1*, *PfMFS6*) independent attempts to obtain TGD cell lines for the other four transporters with the respective plasmids failed, indicating that these genes have an indispensable role in blood stage parasite growth.

To probe into the function of the putative transporters where we were unable to generate gene-disruptions, we utilized the glmS ribozyme sequence. The corresponding sequence was integrated into the 3'UTR of the targeted genes. This enabled the induction of conditional degradation of respective mRNAs upon addition of glucosamine (42) and the assessment of the phenotypic consequences. Upon addition of 2.5 mM glucosamine to young ring stage parasites we found a 76.8% (+/- SD 3.7) reduction in GFP fluorescence intensity in *PfDMT2*-GFP parasites, 72.7% (+/- SD 9.4) reduction in *PfMFS6*-GFP and a 77.7% (+/- SD 6.1) re-

duction in *PfPMRT1*-GFP in schizonts of the same cycle (Figure 2A–C, S4A–C). No measurable reduction in fluorescence intensity could be detected for *PfFVRT1*-GFP or *PfCDF*-GFP expressing parasite lines (Figure S4D–F). Presence of the glmS cassette in both plasmids was confirmed by PCR (Figure S4H). For parasite cell lines with a significant reduction in the expression of the endogenously tagged protein, proliferation was analyzed in the absence and presence of 2.5 mM glucosamine (Figure 2D, S4G). While no significant effect on growth was observed for *PfMFS6*, a growth reduction of 68.5 % (+/- SD 2.1) over two cycles was observed upon knockdown of *PfDMT2*. For *PfPMRT1*, a minor growth delay was measurable, which resulted in a significantly reduced parasitemia at day 3 upon knockdown using 2.5 mM glucosamine (two tailed Wilcoxon rank sum test, $W = 15$, $n_1 = 5$, $n_2 = 3$, $P = 0.03$), but was not significant when using 5 mM glucosamine (two tailed Wilcoxon rank sum test, $W = 10$, $n_1 = 4$, $n_2 = 3$, $P = 0.16$) (Figure 2E). Additionally, significantly fewer newly formed ring stage parasites were observed at 84 hours post invasion (hpi) (Figure 2F), and multiple pairwise post-hoc comparisons using the Conover-Iman rank sum test and Benjamini-Hochberg method to control the false discovery rates showed significant step-wise reductions of ring stage parasites after induction of GlmS-based knockdown of *PfPMRT1* using both, 2.5 mM glucosamine (adjusted $P = 0.0078$) and 5 mM glucosamine (adjusted $P = 0.0005$) in comparison to untreated control cell cultures.

To better characterize the minor growth phenotype of *PfPMRT1*-GFP-glmS parasites that might be due to incomplete knockdown, we generated a conditional *PfPMRT1* knockout cell line (cond Δ PMRT1) using the Dimerizable Cre (DiCre) system (52, 53). Again using the SLI system (41), the endogenous *PfPMRT1* was disrupted upstream of the region encoding the N-terminal transmembrane domain, but, at the same time introducing a recodonized second functional copy of *PfPMRT1* flanked by loxP sites in the genomic locus. This loxP-flanked allelic copy of *PfPMRT1* encodes an additional 3x hemagglutinin (HA) tag, which can be conditionally excised upon addition of a rapamycin analog (rapalog) via the enzymatic activity of an episomally expressed DiCre (Figure 3A). First, correct integration of the plasmid into the genomic locus was verified by PCR (Figure 3B). Second, expression and localization of the recodonized HA-tagged protein at the PPM was verified by colocalization with the merozoite plasma membrane marker MSP1 (54) (Figure 3C). Third, excision of the recodonized gene upon rapalog addition was confirmed on genomic level by PCR (Figure 3D) and on protein level by Western blot analysis at 24 hpi and 48 hpi (Figure 3E). To assess the effect of conditional *PfPMRT1* knockout on parasite proliferation, we determined growth of the transgenic parasite cell line with and without rapalog over five days (Figure 3F, S5A). In contrast to the glmS-based knockdown experiment, DiCre-based gene excision (induced by the addition of rapalog to young ring stages of cond Δ PMRT1 parasite cell cultures) abolished growth within the first replication cycle (Figure 3F, S5A). The specificity of the observed

growth phenotype was verified by gene complementation. To achieve this, we episomally expressed recodonized *PfPMRT1* with TY1-epitope tag either under the constitutive *nmd3* or the weaker *sf3a2* promoter (55) in the *condΔPMRT1* cell line (Figure 3D, F, S5B, C). Correct localization of the TY1-tagged *PfPMRT1* at the PPM was verified by immunofluorescence assays (IFA) (Figure 3G). Notably both, complementation of the *PfPMRT1* knockout cell line (*condΔPMRT1*) with recodonized *PfPMRT1* either under control of the constitutive *nmd3* or the weaker *sf3a2* promoter, restored parasite growth (Figure 3F, S5B, C). The level of growth restoration with low level expression of recodonized *PfPMRT1* is in line with the results from *glmS*-knockdown experiments, which showed that a reduction of about 75% in protein expression resulted only in a minor growth perturbation (Figure 2C, D).

Loss of the PPM-localized *PfPMRT1* leads to an arrest of parasite development at trophozoite stage and the formation of PPM derived protrusions

To determine, which particular parasite stages are affected by the knockout of *PfPMRT1*, we added rapalog to tightly synchronized parasites at different time points (4, 20 and 32 hpi) (Figure 4A) and monitored parasite growth by flow cytometry. Additionally, we quantified growth perturbation by microscopy of Giemsa smears at 4, 20, 24, 32, 40, 48, 72 and 96 hpi (Figure 4B, S6A, B). When adding rapalog at 4 hpi, parasite development progressed through ring and early trophozoite stages up to 24 hpi with no visible abnormality. Afterwards, parasites with deformed and enlarged protrusions started to appear and further development occurred to be stalled. At 32 hpi, almost all parasites had developed to late trophozoites/early schizonts in the control, whereas these stages were completely absent in *PfPMRT1*-deficient parasites. Over 50% of the parasites were pycnotic or possessed large protrusions, the remaining parasites stayed arrested at the trophozoite stage. Quantification of the percentage of parasites with protrusions between 20 hpi and 32 hpi revealed 94.8% (+/- SD 4.0) protrusion-positive parasites (Figure 4C). The activation of gene excision at later time points by adding rapalog at 20 hpi or 32 hpi resulted in no or minor growth perturbation in the first cycle with successful re-invasion, but again led to parasites arresting at the trophozoite stage in the second cycle with an accumulation of protrusions (Figure 4A, S6A, B).

In order to get further insights into the morphological changes in *PfPMRT1*-deficient parasites, we incubated these parasites with dihydroethidium (DHE) to visualize the parasite cytosol (44). We observed an absence of staining within the protrusions, suggesting they are not filled with parasite cytosol (Figure 4D). Next, we transfected the *condΔPMRT1* cell line with a plasmid encoding the PPM marker Lyn-mCherry (41) and observed Lyn-mCherry-positive protrusions upon knockout of *PfPMRT1* starting to become visible at 24 hpi, indicating that the protrusions originate from the PPM (Figure 4E). In line with this, protrusion mem-

branes were also stainable with BODIPY TR C5 ceramide in cond Δ PMRT1 parasites at 32 hpi (Figure 4F).

Depletion of *Pf*PMRT1 results in an early arrest of gametocyte development

RNA-seq data suggest *Pf*PMRT1 is also expressed during other developmental stages, such as gametocytes (56, 57). Therefore, we assessed expression of *Pf*PMRT1-GFP during gametocytogenesis by re-engineering *Pf*PMRT1-GFP-glmS in the inducible gametocyte producer (iGP) '3D7-iGP' (58) parasite line, which allows the robust induction of sexual commitment by conditional expression of gametocyte development 1 protein (GDV1) upon addition of shield-1 (58) (Figure S7A). We show that *Pf*PMRT1 is indeed expressed during all stages of gametocytogenesis and again localizes to the PPM, colocalizing with the PPM-marker Lyn-mCherry (41) (Figure 5A, B). Conditional knockdown of *Pf*PMRT1 via the glmS-ribozyme system (Figure S7B) resulted in a reduction in *Pf*PMRT1-GFP fluorescence intensity of 79.4% (+/- SD 9.2%) at 7 days post induction (dpi) or 75.5% (+/- SD 23.2%) at 10 dpi, without an effect on gametocyte development (Figure S7C–F). In order to exclude that a role of *Pf*PMRT1 in gametocytogenesis is covered by only a partial knockdown resulting in low levels of expressed protein and to determine if *Pf*PMRT1 is essential for gametocytogenesis, we episomally expressed GDV1-GFP-DD in the cond Δ PMRT1 parasite line, enabling conditional induction of sexual commitment upon addition of shield 1 in these parasites (59). Conditional knockout of *Pf*PMRT1 in these transgenic parasites at day three post gametocyte induction resulted in pycnotic parasites from day 5 onwards, while excision of *Pf*PMRT1 at day 5 post induction had no effect on gametocyte development (Figure 5C, D). Excision of the recodonized gene upon rapalog addition was confirmed at a genomic level by PCR for both conditions (Figure 5E). Quantification of parasite stages at day 10 post induction of GDV1 expression revealed 77.9% (+/- SD 7.7%) gametocytes and 22.1% (+/- SD 7.7%) pycnotic parasites in the control, while 100% of parasites were already pycnotic in the cultures, with induced knockout by addition of rapalog at day 3 post gametocyte induction by GDV1 expression (Figure 5F). This data indicates that *Pf*PMRT1 is important for early gametocyte development.

PMRT1 is unique to the genus *Plasmodium* and interspecies complementation assays showed partial functional conservation

*Pf*PMRT1 shows a lack of sequence similarities with known or putative transporters and/or conserved domains shared with known transporter families (2, 5). Our phylogenetic analysis revealed that homologs of *Pf*PMRT1 are present across *Plasmodium* species with amino acid sequence identities of about 90% in the subgenus *Laverania*, but about 50% outside *Laverania* (Figure 6A). However, prediction of the protein structure using AlphaFold (39) indicates two bundles of four transmembrane helices with reasonable similarity of the C-terminal

bundle with the photosynthetic reaction center Maquette-3 protein (60) (RMSD of 3.12) (Figure 6B, Figure S1B). In order to test for functional conservation, we expressed the *PfPMRT1* homologs of *P. vivax* (PVP01_0936100) and *P. knowlesi* (PKNH_0933400) episomally as C-terminal Ty-1 fusion proteins under the *nmd3* promoter in the *condΔPMRT1* parasites. Both fusion proteins are expressed. They were again localized at the PPM as shown by IFA (Figure 6C, Figure S8), and, importantly, were able to partially restore growth after two cycles to 64.8% (+/- SD 9.8%) and 65.1% (+/- SD 7.4%) compared to *condΔPMRT1* parasites (Figure 6D, S8). Excision of the recodonized endogenous *Pfpmrt1* gene upon rapalog addition was confirmed at a genomic level by PCR (Figure 6E). These data indicate that PMRT1 is functionally conserved within the genus *Plasmodium*.

Discussion

In this manuscript we functionally described four so called “orphan transporter” (31) in *P. falciparum*, which were partially characterized in *P. berghei*, and included two additional so far uncharacterized proteins with transporter sequence signature.

We localized *PfFVRT1*-GFP – annotated on PlasmoDB (38) as putative divalent metal transporter – at the food vacuole of the parasite, which is in line with a previously predicted food vacuole association (1) and its reported homology (1, 61) to the conserved eukaryotic endosomal/lysosomal natural resistance-associated macrophage protein (NRAMP) transporter (62) in our structure similarity search. Repeated attempts to generate a TGD cell line failed, indicating an important role of this transporter during asexual blood stage development which is in agreement with data from a *P. falciparum* genome wide essentiality screen (63).

In concordance with recently published data identifying *PbDMT2* and *PbMFS6* as leaderless apicoplast transporters (32), we localized GFP-fusion proteins of *PfDMT2* and *PfMFS6* at the apicoplast. Successful knockdown of *PfDMT2* resulted in a growth defect in the second cycle after induction, resembling the described delayed death phenotype of other apicoplast genes that were functionally inactivated (32, 64–66). It suggests an essential role of *PfDMT2* in apicoplast physiology, as observed by Sayers *et al.* (32) for the rodent malaria *P. berghei*. This is further supported by our failed attempts to disrupt this gene using the SLI system.

We also failed to disrupt the *PfMFS6* locus, which is in agreement with the gene knockout studies in *P. berghei* that led to a markedly decreased multiplication rate (31, 32, 67). Nevertheless, glmS-based knock-down, although comparable to *PfDMT2*-GFP knockdown (72.7% versus 76.8% reduction in GFP fluorescence, respectively) had no effect on parasite proliferation in our study. This might indicate that these reduced levels of *PfMFS6*, in contrast to reduced levels of *PfDMT2*, are sufficient for normal asexual replication *in vitro*.

Another candidate, *PfCDF*, annotated as putative cation diffusion facilitator family protein, showed multiple cytosolic foci within the parasite with no co-localization with apical organelle

markers. The homologue in *Toxoplasma gondii*, TgZnT (TgGT1_251630) shows a similar cellular distribution (68). It has recently been shown to transport Zn^{2+} , to localize to vesicles at the plant-like vacuole in extracellular tachyzoites and to be present at dispersed vesicles throughout the cytoplasm of intracellular tachyzoites (68). The essentiality of PfCDF for *in vitro* blood stage growth is debatable. We were not able to generate a clonal wild-type free TGD cell line although correct integration of the plasmid into the genomic locus could be verified (Figure S3C). This points towards its dispensability for *in vitro* blood stage growth, which is supported by i) its high (1.0) mutagenesis index score in a *P. falciparum* genome-wide mutagenesis screen (63) and ii) gene deletion experiments in rodent malaria species showing that CDF proteins are non-essential for *in vivo* blood stage development in *P. yoelii* (69) and *P. berghei* (31, 67).

Finally, two putative transporters, PfZIP1 and PfPMRT1, localized to the PPM. We show that PfZIP1 is non-essential for *P. falciparum* *in vitro* blood stage development, in line with a high (0.7) mutagenesis index score in a *P. falciparum* genome-wide mutagenesis screen (63). However, this is in contrast to the reported strong fitness loss in *P. berghei* (67) knockout mutants and failed knockout attempts in *P. yoelii* and *P. berghei* *in vivo* mouse models (32, 69). These observations may reflect differences between *Plasmodium* species or differing requirements for *in vitro* and *in vivo* growth conditions.

PfPMRT1 is annotated as a conserved *Plasmodium* membrane protein with unknown function. It has been described as a protein showing structural characteristics of a transporter, without sharing sequence similarities with known or putative transporters and/or conserved domains of known transporter families (2, 5). It encompasses 410 amino acids with eight predicted (70) transmembrane domains (TM) (Figure S1). The N- and C-terminal parts of PfPMRT1 are both predicted (71) to be facing the cytosolic side of the parasite. Surface electrostatics indicate a clear polarity of PfPMRT1 with negative charges facing the parasitophorous vacuole (PV) lumen and positive charges inside the parasite cytosol (Figure S8F). The loops protruding into the PV lumen of PfPMRT1 are generally larger than the cytosolic loops and possess stretches of negatively charged amino acids likely relevant for its transport function. Further functional characterization of PfPMRT1 will deliver insight into its transporter capabilities and its physiological role.

Our phylogenetic analysis confirmed PMRT1 as unique for *Plasmodium* species with high sequence conservation only within the *Laverania* subgenus (72). In line with data from genome-wide mutagenesis screens (63, 67) and reported failed knockout attempts in *P. yoelii* (69), we found that PfPMRT1 is essential for parasite growth, as its functional inactivation resulted in growth arrest at the trophozoite stage accompanied by the accumulation of PPM-derived protrusions within the parasite. In contrast, conditional knockdown resulted only in a growth delay, indicating that minor residual PfPMRT1 protein levels appear to be sufficient to

promote parasite growth. This finding was validated by episomal expression of an allelic copy under the control of the weak *sf3a2* promoter (55) in the *PfPMRT1* knockout parasites. Additionally, we found that *PfPMRT1* is essential for early gametocytogenesis. Interestingly, the induction of the knockout at stage II–III had no effect on gametocytogenesis. This might be due to sufficient amounts of *PfPMRT1* already present at the PPM, but could also indicate that the function of the transporter is not required for later stage gametocyte maturation.

For future work, further functional and pharmacological characterization of this transporter will provide insights into its biological role in different stages of the parasites life cycle, as transcriptomic data indicates – along with expression in blood stages (34, 35) – *PfPMRT1* is expressed in oocysts of *P. falciparum* (73, 74) and *P. berghei* (75).

Material and methods

Cloning of plasmid constructs for parasite transfection

For endogenous tagging using the SLI system (41) a 889 bp (for *PfPMRT1*; PF3D7_1135300), 905 bp (*PfFVRT1*; PF3D7_0523800), 827bp (*PfZIP1*; PF3D7_0609100), 873 bp (*PfDMT2*; PF3D7_0716900), 877 bp (*PfMFS6*; PF3D7_1440800), 785 bp (*PfCDF*; PF3D7_0715900) long homology region (HR) was amplified using 3D7 gDNA and cloned into pSLI-GFP-glmS (76) (derived from pSLI-GFP (41)) using the NotI/MluI restriction site. In order to generate *PfPMRT1*-2xFKBP-GFP a 1000 bp long HR was amplified using 3D7 gDNA and cloned into pSLI-2xFKBP-GFP (41).

For SLI-based targeted gene disruption (SLI-TGD) (41) a 501 bp (*PfPMRT1*), 378 bp (*PfFVRT1*), 511 bp (*PfZIP1*), 399 bp (*PfDMT2*), 396 bp (*PfMFS6*), 741 bp (*PfCDF*) long homology region was amplified using 3D7 gDNA and cloned into the pSLI-TGD plasmid (41) using NotI and MluI restriction sites.

For conditional deletion of *PfPMRT1*, the first 492 bp of the *PfPMRT1* gene were PCR amplified to append a first loxP site and a recodonized T2A skip peptide. The recodonized full-length coding region of *PfPMRT1* was synthesized (GenScript, Piscataway, NJ, USA) and PCR amplified with primers to add a second loxP site after the gene to obtain a second fragment. Both fragments were cloned into pSLI-3xHA (55), using NotI/SpeI and AvrII/XmaI sites. This resulted in plasmid pSLI-*PfPMRT1*-loxP and the resulting transgenic cell line after successful genomic modification was transfected with pSkip-Flox (41) using 2 µg/ml Blasticidin S to obtain a line expressing the DiCre fragments (cond Δ PMRT1).

For complementation constructs, the recodonized *PfPMRT1* gene was PCR amplified using primers to append the TY1 sequence and cloned via XhoI and AvrII or KpnI into pEXP1comp (55) containing yDHODH as a resistance marker and different promoters (*nmd3* (PF3D7_0729300), *sf3a2* (PF3D7_0619900)) driving expression of the expression cassette. This resulted in plasmids c-^{nmdr}*PfPMRT1*-ty1 and c-^{sf3a2}*PfPMRT1*-ty1.

PfPMRT1 homologues of *P. vivax* (PVP01_0936100) (77) and *P. knowlesi* (PKNH_0933400) (78) were amplified from parasite gDNA and cloned into p^{nmd3}EXP1comp (55) via the XhoI/AvrII restriction site. For co-localization experiments the plasmids pLyn-FRB-mCherry (41), P40PX-mCherry (44), pARL-^{crt}ACP-mCherry (46), pARL-^{ama1}ARO-mCherry (49) and pARL-^{ama1}AMA1-mCherry (51) were used. For conditional gametocyte induction yDHODH was amplified by PCR from pARL-^{ama1}AMA1-mCherry-yDHODH (51) and cloned into GDV1-GFP-DD-hDHFR(59)(59) using the XhoI/XhoI restriction site. Oligonucleotides and plasmids used in this study are listed in Table S1A and S1B.

***P. falciparum* culture and transfection**

Blood stages of *P. falciparum* 3D7 were cultured in human erythrocytes (O+). Cultures were maintained at 37°C in an atmosphere of 1% O₂, 5% CO₂ and 94% N₂ using RPMI complete medium containing 0.5% Albumax according to standard protocols (79). To maintain synchronized parasites, cultures were treated with 5% sorbitol (80).

Induction of gametocytogenesis was done as previously described (58, 59). Briefly, GDV1-GFP-DD expression was achieved by addition of 4 µM shield-1 to the culture medium and gametocyte cultures were treated with 50 mM N-acetyl-D-glucosamine (GlcNAc) for five days starting 72 hours post shield-1 addition to eliminate asexual parasites(81). Alternatively, asexual ring stage cultures with >10% parasitemia were synchronized with Sorbitol (80) cultured for 24 hours and treated with 50 mM N-acetyl-D-glucosamine (GlcNAc) (81) for five days.

For transfection, Percoll-purified (82) late-schizont-stage parasites were transfected with 50 µg of plasmid DNA using Amaxa Nucleofector 2b (Lonza, Switzerland) as previously described(83). Transfectants were selected either using 4 nM WR99210 (Jacobus Pharmaceuticals), 2 µg/ml Blasticidin S (Life Technologies, USA), or 0.9 µM DSM1 (84) (BEI Resources; <https://www.beiresources.org>). In order to select for parasites carrying the genomic modification using the SLI system (41), G418 (Sigma-Aldrich, St. Louis, MO) at a final concentration of 400 µg/ml was added to 5% parasitemia culture. The selection process and testing for integration were performed as previously described (41).

For SLI-TGD, a total of six (*PfPMRT1*, *PfDMT2*, *PfZIP1*, *PfCDF*) or eight (*PfFVRT1*, *PfMFS6*) independent 5 ml cultures containing the episomal plasmid were selected under G418 for at least eight weeks.

Imaging and immunofluorescence analysis (IFA)

Fluorescence images of infected erythrocytes were observed and captured using a Zeiss Axioskop 2plus microscope with a Hamamatsu Digital camera (Model C4742-95), a Leica D6B fluorescence microscope equipped with a Leica DFC9000 GT camera and a Leica Plan Apochromat 100x/1.4 oil objective or an Olympus FV3000 with a x100 MPLAPON oil objec-

tive (NA 1.4). Confocal microscopy was performed using a Leica SP8 microscope with laser excitation at 405 nm, 490 nm, and 550 nm for DAPI, GFP, and mCherry excitation, respectively. An HC PL APO 63x NA 1.4 oil immersion objective was used and images were acquired with the HyVolution mode of the LASX microscopy software. After recording, images were deconvolved using Huygens (express deconvolution, setting 'Standard').

Microscopy of unfixed IEs was performed as previously described (85). Briefly, parasites were incubated in RPMI1640 culture medium with Hoechst-33342 (Invitrogen) for 15 minutes at 37°C prior to imaging. 7 µl of IEs were added on a glass slide and covered with a coverslip. Control images of 3D7 wild type parasites across the IDC are included in Figure S8D, E. BODIPY TR C5 ceramide (Invitrogen) staining was performed by adding the dye to 32 hours post invasion parasites in a final concentration of 2.5 µM in RPMI as previously described (85). For DHE staining of the parasite cytosol (44), 80 µl of resuspended parasite culture were incubated with DHE at a final concentration of 4.5 µg/ml in the dark for 15 minutes prior to imaging.

IFAs were performed as described previously (86). Briefly, IEs were smeared on slides and air-dried. Cells were fixed in 100% ice cold methanol for 3 minutes at -20°C. Afterwards, cells were blocked with 5% milk powder for 30 minutes. Next primary antibodies were diluted in PBS/3% milk powder and incubated for 2 hours, followed by three washing steps in PBS. Secondary antibodies were applied for 2 hours in PBS/3% milk powder containing 1 µg/ml Hoechst-33342 (Invitrogen) or DAPI (Roche) for nuclei staining, followed by 3 washes with PBS. One drop of mounting medium (Mowiol 4-88 (Calbiochem)) was added and the slide sealed with a coverslip for imaging.

To assess the localisation of the endogenously HA-tagged *PfPMRT1* IFAs were performed in suspension with Compound 2-stalled schizonts (87) to distinguish protein located at the PPM from that located at the PVM as previously done (55, 88). For this, trophozoite stages were treated with Compound 2 (1 µM) overnight, and arrested schizonts were harvested, washed in PBS, and fixed with 4% paraformaldehyde/0.0075% glutaraldehyde in PBS. Cells were permeabilized with 0.5% Triton X-100 in PBS, blocked with 3% BSA in PBS, and incubated overnight with primary antibodies diluted in 3% BSA in PBS. Cells were washed 3 times with PBS and incubated for 1 hour with Alexa 488 nm or Alexa 594 nm conjugated secondary antibodies specific for human and rat IgG (Invitrogen) diluted 1:2,000 in 3% BSA in PBS and containing 1 µg/ml DAPI. Cells were directly imaged after washing 5 times with PBS

Antisera used: 1:200 mouse anti-GFP clones 7.1 and 13.1 (Roche), 1:500 rat anti-HA clone 3F10 (Roche), 1:1000 human anti-MSP1 (89), 1:10000 mouse anti-TY1 (ThermoFischer Scientific Cat.No: MA5-23513). Contrast and intensities were linear adjusted if necessary and cropped images were assembled as panels using Fiji (90), Corel Photo-Paint X6 and Adobe Photoshop CC 2021.

Immunoblots

For immunoblotting parasites were released from erythrocytes by incubation with 0.03% saponin in PBS for 10 minutes on ice followed by three wash steps with D-PBS. Proteins were then extracted with lysis buffer (4 % SDS, 0.5 % Triton X-100, 0.5x D-PBS in dH₂O) in the presence of protease cocktail inhibitor (Roche) and 1 mM PMSF followed by addition of reducing SDS sample buffer and 5 minutes incubation at 55°C. Parasite proteins were separated on a 10% SDS-PAGE gel using standard procedures and transferred to a nitrocellulose membrane (Amersham™Protran™ 0.45 µm NC, GE Healthcare) using a transblot device (Bio-Rad) according to manufacturer's instructions or to a nitrocellulose membrane (Licor) in a tankblot device (Bio-Rad) using transfer buffer (0.192 M glycine, 0.1% SDS, 25 mM Tris-HCl pH = 8.0) with 20% methanol.

Rabbit anti-aldolase (91) and anti-SBP1 (91) antibodies were diluted 1:2,000, mouse anti-GFP clones 7.1 and 13.1 (Roche) antibody was diluted 1:500 or 1:1,000, mouse anti-Ty1 (Sigma) was diluted 1:20000, rabbit anti-BIP (92) was diluted 1:2500 and rat anti-HA clone 3F10 (Roche) antibody was diluted 1:1,000.

The chemiluminescent signal of the HRP-coupled secondary antibodies (Dianova) was visualized using a Chemi Doc XRS imaging system (Bio-Rad) and processed with Image Lab Software 5.2 (Bio-Rad). To perform loading controls and ensure equal loading of parasite material anti-aldolase antibodies were used. The corresponding immunoblots were incubated two times in stripping buffer (0.2 M glycine, 50 mM DTT, 0.05% Tween 20) at 55°C for 1 hour and washed 3 times with TBS for 10 minutes. For Western blots shown in Figure S8C fluorescent signals of secondary goat anti-rabbit IgG coupled to IRDye® 680CW and goat anti-mouse IgG coupled to IRDye® 800CW were visualized using Odyssey Fc Imager by LI-COR Biosciences.

Growth Assay

A flow cytometry-based assay adapted from previously published assays (44, 93) was performed. For this, parasite cultures were resuspended and 20 µl samples were transferred to an Eppendorf tube. 80 µl RPMI containing Hoechst-33342 and dihydroethidium (DHE) was added to obtain final concentrations of 5 µg/ml and 4.5 µg/ml, respectively. Samples were incubated for 20 minutes (protected from UV light) at room temperature, and parasitemia was determined using an LSRII flow cytometer by counting 100,000 events using the FACSDiva software (BD Biosciences) or using an ACEA NovoCyte flow cytometer.

Stage distribution assay

In order to obtain tightly synchronized parasite cultures, percoll purified schizonts (82) were cultured for four hours together with fresh erythrocytes, followed by sorbitol synchronization and resulting in a four-hour age window of parasites. Next, the culture was divided in four

dishes and rapalog was added at a final concentration of 250 nM immediately to one dish and at 20 hours post invasion (hpi) and 32 hpi to the respective dishes. Giemsa smears and samples for flow cytometry were collected at the indicated timepoints. The parasitemia was determined using a flow cytometry assay and the stages were determined microscopically counting at least 50 infected erythrocytes per sample and timepoint.

Gametocyte stage distribution assay

Giemsa-stained blood smears 10 days post induction of GDV1 expression were obtained and at least 10 fields of view were recorded using a 63x objective per treatment and time point. Erythrocyte numbers were then determined using the automated Parasitemia software (<http://www.gburri.org/parasitemia/>) while the number of gametocytes, pycnotic and asexual parasites was determined manually in >1800 erythrocytes per sample. This assay was done blinded.

GlmS-based knockdown

GlmS based knockdown assay was adapted from previously published assays (42, 76). To induce knockdown 2.5 or 5 mM glucosamine was added to highly synchronous early rings stage parasites. As a control, the same amount of glucosamine was also added to 3D7 wildtype parasites. For all analyses, the growth medium was changed daily, and fresh glucosamine were added every day.

Knockdown was quantified by fluorescence live cell microscopy at day 1 and 3 of the growth assay. Parasites with similar size were imaged, and fluorescence was captured with the same acquisition settings to obtain comparable measurements of the fluorescence intensity. Fluorescence intensity (integrated density) was measured with Fiji(90), and background was subtracted in each image. The data were analyzed with Graph Pad Prism version 8.

GlmS based knockdown experiments in gametocytes were performed as described previously (94). Briefly, synchronized ring stage cultures were induced by the addition of shield-1. At day 3 post induction the culture was split into two dishes and one dish was cultured in the presence of 2.5 mM glucosamine for the remaining ten days. Knockdown was quantified by fluorescence live cell microscopy at day 7 and 10 post induction, as described above and gametocyte parasitemia was determined at day 10 post induction using the automated Parasitemia software (<http://www.gburri.org/parasitemia/>).

DiCre mediated conditional knockout

The parasites containing the integrated pSLI-*PfPMRT1-loxP* construct were transfected with pSkip-Flox (41) using 2 µg/ml Blasticidin S to obtain a line expressing the DiCre fragments. To induce excision, the tightly synchronized parasites (detailed description see growth assay) were split into 2 dishes and rapalog was added to one dish (Clontech, Mountain View, CA) to a final concentration of 250 nM. The untreated dish served as control culture. Excision

was verified at genomic level after 24 and 48 hours of cultivation by PCR and on protein level by Western blot using anti-HA antibodies.

Phylogenetic analysis

A blastp search of the PMRT1 sequence (PlasmoDB (38): PF3D7_1135300; UniProt: Q8II12) was performed against the nr database (9 May 2021) using Geneious Prime 2021.2.2 (<https://www.geneious.com>) and an E-value of 10e-0 (BLOSUM62 substitution matrix). Blast hits were filtered for sequences from taxa represented in the currently favored haemosporidian parasite phylogeny (95). The phylogeny derived from an amino acid alignment using Bayesian framework with a partitioned supermatrix and a relaxed molecular clock (18_amino_acid_partitioned_BEAST_relaxed_clock_no_outgroup.tre; (95)) was visualized with associated data using the R package ggtree v3.3.0.900 (96, 97). A multiple protein sequence alignment of PMRT1 and homologous sequences was performed using MAFFT v7.490 (98) using the G-INS-I algorithm to obtain a highly accurate alignment. Protein statistics were calculated using Geneious Prime 2021.2.2 (<https://www.geneious.com>) and EMBOSS pepstats v6.6.0.0 (99).

Prediction of protein structures

AlphaFold structure predictions (39) were retrieved from <https://alphafold.ebi.ac.uk> and the PDB used for DALI protein structure homology search (40). PyMOL Molecular Graphics System, Version 2.5.2 Schrödinger was used for visualization of all structures, generation of figures and the calculation of the root mean square deviation (RMSD) between the predicted crystal structure of *Pf*PMRT1 and the Maquette-3 protein (PDB: 5vjt (60)) by cealign. The Adaptive Poisson-Boltzmann Solver (APBS) within PyMOL was used to predict the surface electrostatics of *Pf*PMRT1.

Parasite icons were generated using BioRender (biorender.com), plasmids and oligonucleotides were designed using ApE (100) and statistical analysis was performed using GraphPad Prism version 8 (GraphPad Software, USA).

Acknowledgements

We thank Michael Filarsky for providing the pHcamGDV1-GFP-DD_hDHFR plasmid, Egbert Tannich for providing *P. vivax* and *P. knowlesi* gDNA, Mike Blackman for the anti-MSP1 antibody, Jacobus Pharmaceuticals for WR99210, Greg Burri for the parasitemia software and the Advanced Light and Fluorescence Microscopy (ALFM) facility at the Centre for Structural Systems Biology (CSSB), in particular Roland Thuenauer, for support with light microscopy image recording and analysis. DSM1 (MRA-1161) was obtained from MR4/BEI Resources, NIAID, NIH. Furthermore, we thank Maria Rosenthal for her help with the visualization of the predicted protein structures.

Funding

AB and JSW were funded by the German Research Foundation (DFG) grant BA 5213/3-1. Partnership of Universität Hamburg and DESY (PIER) project ID PIF-2018-87 (JSTR, CL, TWG), CSSB Seed grant KIF 2019/002 (TWG), Hospital Research Foundation Fellowship (DW), DAAD/Universities Australia joint research co-operation scheme (TWG, DW, BL). IH and BL were supported by Australian Government Research Training Stipend. JY, SG and GN were funded by DFG Projektnummer 374031971 TRR 240 A04 and 417451587. JSTÄ thanks the Jürgen Manchot Stiftung for funding and PMR, TS acknowledge funding by the DFG (SP1209/4-1)

Author contribution

Conceptualization: JSW, TWG, AB, JSTR
Methodology: GN, SG
Investigation: JSW, PMR, JY, GF; JSTÄ, HVT, AA, IH, BL
Formal Analysis: JSTR
Writing original manuscript: JSW, AB, JSTR, DW
Review & Editing: JSW, PMR, TWG, AB, JSTR, DW
Funding Acquisition: DW, CL, TWG, AB, JSTR
Resources: TWG
Project Administration: TWG, AB, JSTR
Supervision: DW, TS, SG, TWG, AB
All authors read and approved the manuscript.

Figures

Figure 1: Subcellular localization of six putative *P. falciparum* transporters during asexual blood stage development.

(A) Schematic representation of endogenous tagging strategy using the selection-linked integration system (SLI). pink, human dihydrofolate dehydrogenase (hDHFR); grey, homology region (HR); green, green fluorescence protein (GFP) tag; dark grey, T2A skip peptide; blue, neomycin resistance cassette; orange, glmS cassette. Stars indicate stop codons, and arrows depict primers (P1 to P4) used for the integration check PCR. (B–G) Localization of (B) *PfFVRT1*-GFP-glmS, (C) *PfZIP1*-GFP-glmS, (D) *PfCDF*-GFP-glmS, (E) *PfDMT2*-GFP-glmS, (F) *PfMFS6*-GFP-glmS and (G) *PfPMRT1*-GFP-glmS by live-cell microscopy in ring, trophozoite and schizont stage parasites. Nuclei were stained with Hoechst-33342. (H) Co-localization of the GFP-tagged putative transporters with marker proteins P40PX-mCherry (food vacuole), ACP-mCherry (apicoplast), Lyn-mCherry (parasite plasma membrane), ARO-

625 mCherry (rhoptry) and AMA1-mCherry (microneme) as indicated. Nuclei were stained with
626 Hoechst- 33342. Scale bar, 2 μ m.
627

628 **Figure 2: Conditional knockdown of putative transporter indicate importance of**
629 ***PfDMT2* and *PfPMRT1* for parasites fitness.**

630 **(A–C)** Live cell microscopy and quantification of knockdown by measuring mean fluores-
631 cence intensity (MFI) density and size (area) of (A) *PfDMT2*-GFP-glmS (B) *PfMFS6*-GFP-
632 glmS and (C) *PfPMRT1*-GFP-glmS parasites 40 hours after treatment without (control) or
633 with 2.5 mM glucosamine. Scale bar, 2 μ m. Statistics are displayed as mean \pm SD of three
634 (A–B) or four (C) independent experiments and individual data points are color-coded by ex-
635 periments according to Superplots guidelines (101). P-values displayed were determined
636 with two-tailed unpaired t-test. **(D)** Growth of parasites treated without (control) or with 2.5
637 mM glucosamine determined by flow cytometry is shown as relative parasitemia values after
638 two cycles. Shown are means \pm SD of three (*PfPMRT1*-GFP-glmS, *PfDMT2*-GFP-glmS,
639 *PfMFS6*-GFP-glmS) and five (3D7 wild type parasites) independent growth experiments. P-
640 values displayed were determined with unpaired t test with Welch correction and Benjamin-
641 Hochberg for multiple testing correction. Individual growth curves are shown in **Figure S4G**.
642 **(E)** Growth of *PfPMRT1*-glmS and 3D7 parasites after treatment with 2.5 mM (left panel) and
643 5 mM glucosamine (right panel) compared to untreated control parasites over five consecu-
644 tive days. P-values displayed were determined for comparison between *PfPMRT1*-glmS and
645 3D7 parasites at day 3 using two-tailed Wilcoxon rank sum test. **(F)** Mean \pm SD distribution
646 of ring and schizont stage parasites in *PfPMRT1*-glmS and 3D7 cell lines treated without
647 (control), with 2.5 mM or 5 mM glucosamine at 84 hpi (80 hours post addition of glucosa-
648 mine) of three independent experiments. P-values displayed were determined using the
649 Conover-Iman rank sum test and Benjamini-Hochberg method for multiple testing correction
650 after Kruskal-Wallis testing.

651 **Figure 3: *PfPMRT1* is essential for asexual blood stage development.**

652 **(A)** Simplified schematic of DiCre-based conditional *PfPMRT1* knockout using selection-
653 linked integration (SLI). Pink, human dihydrofolate dehydrogenase (hDHFR); grey, homology
654 region (HR); green, T2A skip peptide; light blue, recodonized *PfPMRT1*; dark blue, 3xHA tag,
655 yellow, neomycin phosphotransferase resistance cassette; orange, loxp sequence. Scissors
656 indicate DiCre mediated excision sites upon addition of rapalog. Stars indicate stop codons,
657 and arrows depict primers (P1 to P5) used for the integration check PCR and excision PCR.
658 **(B)** Diagnostic PCR of unmodified wildtype and transgenic cond Δ PMRT1 knock-in (KI) cell
659 line to check for genomic integration using Primer P1-P4 as indicated in (A). **(C)** Immunofluo-
660 rescence assay (IFA) of cond Δ PMRT1 late stage schizont parasites showing localization of

PfPMRT1-3xHA at the parasite plasma membrane (PPM) co-localizing with the merozoite surface protein 1 (MSP1). **(D)** Diagnostic PCR to verify the excision at genomic level at 24 hpi / 20 hours post rapalog addition for *condΔPMRT1* and at 48 hpi for *condΔPMRT1*, *c-nmd3**PfPMRT1*-ty1 and *c-sf3a2**PfPMRT1*-ty1 parasites using Primer P1-P5 as indicated in (A). Black arrow head, original locus; red arrow head, excised locus. **(E)** Western blot using α-HA to verify knockout of *PfPMRT1* on protein level 4, 24 and 48 hours post invasion. Expected molecular weight of *PfPMRT1*-3xHA: 53.3 kDa. Antibodies detecting Aldolase and SBP1 were used as loading controls. **(F)** Growth curves of *condΔPMRT1*, *c-nmd3**PfPMRT1*-ty1 and *c-sf3a2**PfPMRT1*-ty1 parasites +/- rapalog monitored over five days by flow cytometry. One representative growth curve is depicted (replicates in Figure S5). Summary is shown as relative parasitemia values, which were obtained by dividing the parasitemia of rapalog treated cultures by the parasitemia of the corresponding untreated ones. Shown are means +/- SD of three (*condΔPMRT1*, *c-nmd3**PfPMRT1*-ty1) or four (*c-sf3a2**PfPMRT1*-ty1) independent growth experiments. **(G)** IFA of *condΔPMRT1* complemented with C-terminal TY1-tagged *PfPMRT1* constructs expressed either under the constitutive *nmd3* or the weak *sf3a2* promoter to verify PPM localization. Scale bar, 2 μm.

Figure 4: Knockout of *PfPMRT1* results in accumulation of PPM-derived protrusions and growth arrest at the trophozoite stage.

(A) Parasite stage distribution in Giemsa smears displayed as heatmap showing percentage of parasite stages for tightly synchronized (+/- 2 h) 3D7 control and *condΔPMRT1* (rapalog treated at 4 hpi, 20 hpi or 32 hpi) parasite cultures over two consecutive cycles. A second replicate is shown in Figure S6A **(B)** Giemsa smears of control and at 4 hpi rapalog treated *condΔPMRT1* parasites over two cycles. Scale bar, 5 μm. **(C)** Live cell microscopy of 4 hour window synchronized 3D7 control and *condΔPMRT1* parasites +/- rapalog stained with dihydroethidium (DHE) at 20–32 hpi. **(D)** Quantification of parasites displaying protrusions (green) for 4 hour window synchronized 3D7 control and rapalog treated *condΔPMRT1* parasites. Shown are percentages of normal parasites versus parasites displaying protrusions as means +/- SD of three independent experiments. **(E)** Live cell microscopy of 8 hour window synchronized 3D7 control and rapalog treated *condΔPMRT1* parasites, episomally expressing the PPM marker Lyn-mCherry at 24–40 hpi. **(F)** Live cell microscopy of 3D7 control and *condΔPMRT1* parasites +/- rapalog stained with BODIPY TR C5 ceramide at 32 hpi. Scale bar, 2 μm.

Figure 5: *PfPMRT1* is essential for early gametocyte development.

(A) Live cell microscopy of 3D7-iGP-*Pf*PMRT1-GFP parasites across the complete gametocyte development. White arrow heads indicate remaining GDV1-GFP signal observed in close proximity to the Hoechst signal, as previously reported (59, 94, 102, 103). **(B)** Live cell microscopy of *Pf*PMRT1-GFP parasites expressing the PPM marker Lyn-mCherry. Nuclei were stained with Hoechst-33342. Scale bar, 2 μ m. **(C)** Experimental setup of gametocyte induction upon GDV1-GFP-DD expression (+shield-1) and conditional *Pf*PMRT1 knockout (+rapalog) and elimination of asexual blood stage parasites (+GlcNac). **(D)** Gametocyte development over 12 days of cond Δ PMRT1/GDV1-GFP-DD or 3D7-iGP parasites without (control) or with rapalog addition at day 3 (3 dpi) or day 5 (5 dpi) after induction of sexual commitment by conditional expression of GDV1-GFP upon addition of shield-1. Scale bar, 5 μ m. **(E)** Diagnostic PCR to verify the excision on genomic level at 5 dpi and 12 dpi. Black arrow head, original locus; red arrow head, excised locus. **(F)** Representative Giemsa smears and quantification of parasite stage distribution at day 10 post induction for parasites treated without (control) or with rapalog at day 3 post induction. For each condition parasitemia and parasite stages distribution in (Δ PMRT1: $n_{\text{control}} = 3370, 2304, 2759$ and $n_{\text{rapalog}} = 3010, 1830, 2387$; 3D7-iGP: $n_{\text{control}} = 4985, 4685, 5206$ and $n_{\text{rapalog}} = 4930, 4332, 5384$) erythrocytes of three independent experiments were determined and are displayed as percentage. Nuclei were stained with Hoechst-33342. Scale bar, 10 μ m.

Figure 6: PMRT1 is a genus-specific transporter with conserved function.

(A) Phylogenetic tree of haemosporidian parasites (modified from (95)) containing PMRT1 homologous sequences associated with data on pairwise amino acid sequence identity to *Pf*PMRT1. The phylogeny is derived from Bayesian Inference using BEAST using a fully partitioned amino acid dataset and lognormal relaxed molecular clock (95). Silhouettes depict representatives of the vertebrate hosts for each lineage and white filled bars indicate pairwise identities of PMRT1 homologs used for subsequent complementation assays. **(B)** Structural alignment of predicted *Pf*PMRT1 structure with Maquette-3 protein (PDB: 5vjt) (60). Both structures have a root mean square deviation (RMSD) over the aligned α -carbon position of 3.12 over 184 residues calculated in PyMol. **(C)** IFA of c-*nmd3**Pk*-ty1 and c-*nmd3**Pv*-ty1 parasites to verify correct localization of the expressed complementation fusion proteins at the parasite plasma membrane. Nuclei were stained with Hoechst-33342. Scale bar, 2 μ m. **(D)** Growth of cond Δ PMRT1 parasites complemented with *Pf*PMRT1 homologs from *P. vivax* (PVP01_0936100) and *P. knowlesi* (PKNH_0933400). Shown are relative parasitemia values, which were obtained by dividing the parasitemia of rapalog treated cultures by the parasitemia of the corresponding untreated controls together with means \pm SD from three c-*nmd3**Pf*-ty1 (\triangleq c-*nmd3**Pf*PMRT1-ty1 Figure 3D, S5B) and six (c-*nmd3**Pk*-ty1, c-*nmd3**Pv*-ty1) independent growth experiments. One sample t-test **(E)** Diagnostic PCR to verify the excision of

PfPMRT1 on genomic level at 48 hpi for c-^{nmd3}*Pf*-ty1, c-^{nmd3}*Pk*-ty1 and c-^{nmd3}*Pv*-ty1 para-sites. Black arrow head, original locus; red arrow head, excised locus.

Figure S1: Structure predictions and structure homology search of candidate proteins

(A) AlphaFold structure predictions of the six selected orphan transporters visualized in PyMol. (B) Results from protein structure comparison server Dali using the AlphaFold-generated PDB files of the selected transporters as input structure. Shown are the top five non-redundant hits with Z score (significance estimate), msd (difference between the root-mean-square-deviation (rmsd) value associated with a protein structure pair and the rmsd value that would have been observed in the case that the two structures had the same crystallographic resolution), lali (number of aligned positions), nres (number of residues in the matched structure) and %id (the percentage sequence identity in the match).

Figure S2: Validation of generated transgenic cell lines by PCR and Western blot.

(A) Confirmatory PCR of unmodified wildtype (WT) and transgenic knock-in (KI) cell lines (PF3D7_0523800-GFP-glmS (*PfFVRT1*), PF3D7_0609100-GFP-glmS (*PfZIP1*), PF3D7_0715900-GFP-glmS (*PfCDF*), PF3D7_0716900-GFP-glmS (*PfDMT2*), PF3D7_1440800-GFP-glmS (*PfMFS6*) and PF3D7_1135300-GFP-glmS (*PfPMRT1*)) to check for genomic integration at the 3'- and 5'-end of the locus. Position of the primer used are indicated with numbered arrows in Figure 1A. (B) Western Blot analysis of wildtype (3D7) and knock-in (KI) cell lines using mouse anti-GFP to detect the tagged full-length protein (upper panel) and rabbit anti-aldolase to control for equal loading (lower panel). Protein size is indicated in kDa. Expected molecular weight for GFP fusion proteins: *PfFVRT1* (107.5 kDa), *PfZIP1* (69.0 kDa), *PfDMT2* (66.4 kDa), *PfMFS6* (98.8 kDa), *PfPMRT1* (77.5 kDa), *PfCDF* (91.6 kDa) (C) Localization of *PfCDF*-3xHA by IFA in ring, trophozoite and schizont parasites. Nuclei were stained with Hoechst. Diagnostic PCR of unmodified wildtype (WT) and transgenic knock-in (KI) cell line. (D) Localization of *PfPMRT1*-2xFKBP-GFP across the IDC. Nuclei were stained with DAPI. Scale bar, 2 µm. Diagnostic PCR of unmodified wildtype (WT) and transgenic knock-in (KI) cell line. (E) Localization of *PfZIP1*-GFP in merozoites. Nuclei were stained with DAPI. Scale bar, 2 µm. (F) Confocal microscopy of *PfPMRT1*-GFP co-expressing the PPM marker Lyn-mCherry. Scale bar, 1µm. Nuclei were stained with Hoechst.

Figure S3: Targeted gene disruption (TGD) of *PfZIP1* and *PfCDF*.

A) Schematic representation of TGD strategy using the selection-linked integration system (SLI). pink, human dihydrofolate dehydrogenase (hDHFR); grey, homology region (HR);

green, green fluorescence protein (GFP) tag; dark grey, T2A skip peptide; blue, neomycin resistance cassette. Stars indicate stop codons, and arrows depict primers (P1 to P4) used for the integration check PCR. **(B)** Localization of *PfZIP1*-TGD-GFP in ring, trophozoite and schizont parasites. Nuclei were stained with Hoechst-33342. Scale bar, 2 μ m. Confirmatory PCR of unmodified wildtype (WT) and transgenic targeted gene disruption (TGD) cell line. Growth curves of *PfZIP1*-TGD vs. 3D7 parasites monitored over five days by FACS. Three independent growth experiments were performed and a summary is shown as percentage of growth compared to 3D7 parasites. **(C)** Localization of *PfCDF*-TGD in ring, trophozoite and schizont parasites. Nuclei were stained with DAPI. Confirmatory PCR of unmodified wildtype (WT) and transgenic targeted gene disruption (TGD) cell line. Scale bar, 1 μ m.

Figure S4: Conditional knockdown via glmS system.

Live cell microscopy of **(A)** *PfFVRT1*-GFP-glmS, **(B)** *PfCDF*-GFP-glmS, **(C)** *PfZIP1*-GFP-glmS **(D)** *PfDMT2*-GFP-glmS, **(E)** *PfMFS6*-GFP-glmS and **(F)** *PfPMRT1*-GFP-glmS parasites 40 hours after treatment without (control) or with 2.5 mM Glucosamine. Nuclei were stained with Hoechst-33342. Scale bar, 2 μ m. **(G)** Individual growth curves of the growth assays shown in **Figure 2D**. **(H)** PCR using a GFP forward and glmS reverse primer confirming the presence of the GFP and glmS sequence in the pSLI-*PfFVRT1*-GFP-glmS and *PfCDF*-GFP-glmS plasmids. pSLI-PF3D7_0631900-GFP (35) was used as negative control.

Figure S5: Conditional knockout of *PfPMRT1* via DiCre-based system

Replicates of growth curves of *condΔPMRT1*, *c^{nmd3}PfPMRT1*-ty1 and *c^{sf3a2}PfPMRT1*-ty1 parasites +/- rapalog monitored over five days by FACS shown in **Figure 3**.

Figure S6: Conditional knockout of *PfPMRT1*

(A) Parasite stage distribution in Giemsa smears displayed as heatmap showing percentage of stages for control, 4 hpi, 20 hpi or 32 hpi rapalog treated 4 hour window synchronized *condΔPMRT1* parasite cultures over one cycle. **(B)** Giemsa smears of control and 4 hpi, 20 hpi or 32 hpi rapalog treated parasites at 4, 16, 20, 24, 32, 40 and 48 hpi. Scale bar, 5 μ m.

Figure S7: Conditional knockdown of *PfPMRT1* has no effect during gametocyte development.

(A) Confirmatory PCR of unmodified wildtype (WT) and transgenic 3D7-iGP-*PfPMRT1*-GFP-glmS to check for genomic integration at the 3'- and 5'-end of the locus. Position of the primer used are indicated with numbered arrows in **Figure 1A**. **(B)** Schematic representation of

the experimental setup. **(C)** Live cell microscopy of 3D7-iGP-*Pf*PMRT1-GFP stage I – V gametocytes. Scale bar, 2 μ m. **(D)** Giemsa smears of stage I – V gametocytes cultured either without (control) or with 2.5 mM glucosamine. Scale bar, 5 μ m. **(E)** Quantification of knock-down by measuring mean fluorescence intensity (MFI) density and size (area) of parasites at day 7 and day 12 post induction of gametocytogenesis cultured either without (control) or with 2.5 mM glucosamine. Scale bar, 2 μ m. Statistics are displayed as mean \pm SD of four independent experiments and individual data points are displayed as scatterplot color-coded by experiments according to Superplots guidelines(101)(101). P-values displayed were determined with two-tailed unpaired t-test. **(F)** For each condition gametocytemia at day 10 post gametocyte induction was determined by counting between 1256-2653 (mean 2147) cells per condition in Giemsa-stained thin blood smears. Displayed are means \pm SD of independent growth experiments with the number of experiments (n) indicated. P-values displayed were determined with two-tailed unpaired t-test.

Figure S8: Individual growth curves of c-^{nmd3}*Pk*-ty1 **(A)** and c-^{nmd3}*Pv*-ty1 **(B)** parasites +/- rapalog monitored over two IDCs by FACS shown in **Figure 6**. **(C)** Western Blot analysis of c-^{nmd3}*Pf*-ty1, c-^{nmd3}*Pk*-ty1 and c-^{nmd3}*Pv*-ty1 cell lines using mouse anti-ty1 to detect the tagged full-length protein (upper panel) and rabbit anti-BIP to control for loading (lower panel). Protein size is indicated in kDa. **(D)** and **(E)** 3D7 wild type parasites imaged across the IDC to establish autofluorescence levels with Zeiss Axioskop 2plus microscope (D) or Leica D6B fluorescence microscope (E). **(F)** Surface electrostatics of the predicted *Pf*PMRT1 structure generated by APBS within PyMol.

Table S1: Oligonucleotides and plasmids used in this study

References

1. Martin RE, Henry RI, Abbey JL, Clements JD, Kirk K. 2005. The “permeome” of the malaria parasite: an overview of the membrane transport proteins of *Plasmodium falciparum*. *Genome Biol* 6:R26.
2. Martin RE. 2020. The transportome of the malaria parasite. *Biol Rev Camb Philos Soc* 95:305–332.
3. Gardner MJ, Hall N, Fung E, White O, Berriman M, Hyman RW, Carlton JM, Pain A, Nelson KE, Bowman S, Paulsen IT, James K, Eisen JA, Rutherford K, Salzberg SL, Craig A, Kyes S, Chan M-S, Nene V, Shallom SJ, Suh B, Peterson J, Angiuoli S,

- 838 Pertea M, Allen J, Selengut J, Haft D, Mather MW, Vaidya AB, Martin DMA, Fairlamb
839 AH, Fraunholz MJ, Roos DS, Ralph SA, McFadden GI, Cummings LM, Subramanian
840 GM, Mungall C, Venter JC, Carucci DJ, Hoffman SL, Newbold C, Davis RW, Fraser
841 CM, Barrell B. 2002. Genome sequence of the human malaria parasite *Plasmodium*
842 *falciparum*. *Nature* 419:498–511.
- 843 4. Martin RE, Ginsburg H, Kirk K. 2009. Membrane transport proteins of the malaria
844 parasite. *Mol Microbiol*. John Wiley & Sons, Ltd (10.1111).
- 845 5. Weiner J, Kooij TWA. 2016. Phylogenetic profiles of all membrane transport proteins
846 of the malaria parasite highlight new drug targets. *Microb Cell* 3:511–521.
- 847 6. Garten M, Nasamu AS, Niles JC, Zimmerberg J, Goldberg DE, Beck JR. 2018. EXP2
848 is a nutrient-permeable channel in the vacuolar membrane of *Plasmodium* and is
849 essential for protein export via PTEX. *Nat Microbiol* 1.
- 850 7. Desai SA, Krogstad DJ, McCleskey EW. 1993. A nutrient-permeable channel on the
851 intraerythrocytic malaria parasite. *Nature* 362:643–646.
- 852 8. Nguitragool W, Bokhari AAB, Pillai AD, Rayavara K, Sharma P, Turpin B, Aravind L,
853 Desai SA. 2011. Malaria parasite *clag3* genes determine channel-mediated nutrient
854 uptake by infected red blood cells. *Cell* 145:665–677.
- 855 9. Dean P, Major P, Nakjang S, Hirt RP, Martin Embley T. 2014. Transport proteins of
856 parasitic protists and their role in nutrient salvage. *Front Plant Sci*. Frontiers Research
857 Foundation.
- 858 10. Foote SJ, Thompson JK, Cowman AF, Kemp DJ. 1989. Amplification of the multidrug
859 resistance gene in some chloroquine-resistant isolates of *P. falciparum*. *Cell* 57:921–
860 930.
- 861 11. Fidock DA, Nomura T, Talley AK, Cooper RA, Dzekunov SM, Ferdig MT, Ursos LMB,
862 Bir Singh Sidhu A, Naudé B, Deitsch KW, Su XZ, Wootton JC, Roepe PD, Wellems
863 TE. 2000. Mutations in the *P. falciparum* digestive vacuole transmembrane protein
864 PfCRT and evidence for their role in chloroquine resistance. *Mol Cell* 6:861–871.
- 865 12. Veiga MI, Dhingra SK, Henrich PP, Straimer J, Gnädig N, Uhlemann AC, Martin RE,
866 Lehane AM, Fidock DA. 2016. Globally prevalent PfMDR1 mutations modulate
867 *Plasmodium falciparum* susceptibility to artemisinin-based combination therapies. *Nat*
868 *Commun* 7.
- 869 13. Rijpma SR, Van Der Velden M, Bilos A, Jansen RS, Mahakena S, Russel FGM,

- 870 Sauerwein RW, Van De Wetering K, Koenderink JB. 2016. MRP1 mediates folate
871 transport and antifolate sensitivity in *Plasmodium falciparum*. *FEBS Lett* 590:482–492.
- 872 14. Mesén-Ramírez P, Bergmann B, Elhabiri M, Zhu L, Thien H von, Castro-Peña C,
873 Gilberger T-W, Davioud-Charvet E, Bozdech Z, Bachmann A, Spielmann T. 2021. The
874 parasitophorous vacuole nutrient pore is critical for drug access in malaria parasites
875 and modulates the fitness cost of artemisinin resistance. *Cell Host Microbe* 0:283.
- 876 15. Cowman AF, Galatis D, Thompson JK. 1994. Selection for mefloquine resistance in
877 *Plasmodium falciparum* is linked to amplification of the *pfmdr1* gene and cross-
878 resistance to halofantrine and quinine. *Proc Natl Acad Sci U S A* 91:1143–1147.
- 879 16. Mok S, Liong KY, Lim EH, Huang X, Zhu L, Preiser PR, Bozdech Z. 2014. Structural
880 polymorphism in the promoter of *pfmrp2* confers *Plasmodium falciparum* tolerance to
881 quinoline drugs. *Mol Microbiol* 91:918–934.
- 882 17. Lim MYX, LaMonte G, Lee MCS, Reimer C, Tan BH, Corey V, Tjahjadi BF, Chua A,
883 Nachon M, Wintjens R, Gedeck P, Malleret B, Renia L, Bonamy GMC, Ho PCL, Yeung
884 BKS, Chow ED, Lim L, Fidock DA, Diagana TT, Winzeler EA, Bifani P. 2016. UDP-
885 galactose and acetyl-CoA transporters as *Plasmodium* multidrug resistance genes.
886 *Nat Microbiol* 1.
- 887 18. Richards SN, Nash MN, Baker ES, Webster MW, Lehane AM, Shafik SH, Martin RE.
888 2016. Molecular Mechanisms for Drug Hypersensitivity Induced by the Malaria
889 Parasite's Chloroquine Resistance Transporter. *PLoS Pathog* 12.
- 890 19. Cowell AN, Istvan ES, Lukens AK, Gomez-Lorenzo MG, Vanaerschot M, Sakata-Kato
891 T, Flannery EL, Magistrado P, Owen E, Abraham M, La Monte G, Painter HJ, Williams
892 RM, Franco V, Linares M, Arriaga I, Bopp S, Corey VC, Gnädig NF, Coburn-Flynn O,
893 Reimer C, Gupta P, Murithi JM, Moura PA, Fuchs O, Sasaki E, Kim SW, Teng CH,
894 Wang LT, Akidil A, Adjalley S, Willis PA, Siegel D, Tanaseichuk O, Zhong Y, Zhou Y,
895 Llinás M, Otilie S, Gamo FJ, Lee MCS, Goldberg DE, Fidock DA, Wirth DF, Winzeler
896 EA. 2018. Mapping the malaria parasite druggable genome by using in vitro evolution
897 and chemogenomics. *Science (80-)* 359:191–199.
- 898 20. Rocamora F, Gupta P, Istvan ES, Luth MR, Carpenter EF, Kümpornsin K, Sasaki E,
899 Calla J, Mittal N, Carolino K, Owen E, Llinás M, Otilie S, Goldberg DE, Lee MCS,
900 Winzeler EA. 2021. PfMFR3: A Multidrug-Resistant Modulator in *Plasmodium*
901 *falciparum*. *ACS Infect Dis* 7:811–825.
- 902 21. Kirk K. 2004. Channels and transporters as drug targets in the *Plasmodium*-infected

903 erythrocyte. *Acta Trop* 89:285–298.

904 22. Koenderink JB, Kavishe RA, Rijpma SR, Russel FGM. 2010. The ABCs of multidrug
905 resistance in malaria. *Trends Parasitol.* *Trends Parasitol.*

906 23. Murithi JM, Deni I, Pasaje CFA, Okombo J, Bridgford JL, Gnädig NF, Edwards RL,
907 Yeo T, Mok S, Burkhard AY, Coburn-Flynn O, Istvan ES, Sakata-Kato T, Gomez-
908 Lorenzo MG, Cowell AN, Wicht KJ, Le Manach C, Kalantarov GF, Dey S, Duffey M,
909 Laleu B, Lukens AK, Otilie S, Vanaerschot M, Trakht IN, Gamo F-J, Wirth DF,
910 Goldberg DE, Odom John AR, Chibale K, Winzeler EA, Niles JC, Fidock DA. 2021.
911 The Plasmodium falciparum ABC transporter ABCI3 confers parasite strain-dependent
912 pleiotropic antimalarial drug resistance. *Cell Chem Biol* 0.

913 24. Counihan NA, Modak JK, de Koning-Ward TF. 2021. How Malaria Parasites Acquire
914 Nutrients From Their Host. *Front Cell Dev Biol* 9:582.

915 25. Saliba KJ, Horner HA, Kirk K. 1998. Transport and metabolism of the essential vitamin
916 pantothenic acid in human erythrocytes infected with the malaria parasite Plasmodium
917 falciparum. *J Biol Chem* 273:10190–10195.

918 26. Gulati S, Ekland EH, Ruggles K V., Chan RB, Jayabalasingham B, Zhou B, Mantel
919 PY, Lee MCS, Spottiswoode N, Coburn-Flynn O, Hjelmqvist D, Worgall TS, Marti M,
920 Di Paolo G, Fidock DA. 2015. Profiling the Essential Nature of Lipid Metabolism in
921 Asexual Blood and Gametocyte Stages of Plasmodium falciparum. *Cell Host Microbe*
922 18:371–381.

923 27. Mamoun C Ben, Prigge ST, Vial H. 2010. Targeting the lipid metabolic pathways for
924 the treatment of malaria. *Drug Dev Res.* John Wiley & Sons, Ltd.

925 28. Garten M, Beck JR. 2021. Structured to conquer: transport across the Plasmodium
926 parasitophorous vacuole. *Curr Opin Microbiol.* Elsevier Ltd.

927 29. Kloehn J, Lacour CE, Soldati-Favre D. 2021. The metabolic pathways and
928 transporters of the plastid organelle in Apicomplexa. *Curr Opin Microbiol* 63:250–258.

929 30. Beck JR, Ho CM. 2021. Transport mechanisms at the malaria parasite-host cell
930 interface. *PLoS Pathog.* Public Library of Science.

931 31. Kenthirapalan S, Waters AP, Matuschewski K, Kooij TWA. 2016. Functional profiles of
932 orphan membrane transporters in the life cycle of the malaria parasite. *Nat Commun*
933 7:10519.

934 32. Sayers CP, Mollard V, Buchanan HD, McFadden GI, Goodman CD. 2018. A genetic

- 935 screen in rodent malaria parasites identifies five new apicoplast putative membrane
936 transporters, one of which is essential in human malaria parasites. *Cell Microbiol*
937 20:e12789.
- 938 33. Ginsburg H. 2006. Progress in in silico functional genomics: the malaria Metabolic
939 Pathways database. *Trends Parasitol* 22:238–240.
- 940 34. Otto TD, Wilinski D, Assefa S, Keane TM, Sarry LR, Böhme U, Lemieux J, Barrell B,
941 Pain A, Berriman M, Newbold C, Llinás M. 2010. New insights into the blood-stage
942 transcriptome of *Plasmodium falciparum* using RNA-Seq. *Mol Microbiol* 76:12–24.
- 943 35. Wichers JS, Scholz JAM, Strauss J, Witt S, Lill A, Ehnold LI, Neupert N, Liffner B,
944 Lühken R, Petter M, Lorenzen S, Wilson DW, Löw C, Lavazec C, Bruchhaus I,
945 Tannich E, Gilberger TW, Bachmann A. 2019. Dissecting the gene expression,
946 localization, membrane topology, and function of the *plasmodium falciparum* STEVOR
947 protein family. *MBio* 10:e01500-19.
- 948 36. Treeck M, Sanders JL, Elias JE, Boothroyd JC. 2011. The phosphoproteomes of
949 *plasmodium falciparum* and *toxoplasma gondii* reveal unusual adaptations within and
950 beyond the parasites' boundaries. *Cell Host Microbe* 10:410–419.
- 951 37. Pease BN, Huttlin EL, Jedrychowski MP, Talevich E, Harmon J, Dillman T, Kannan N,
952 Doerig C, Chakrabarti R, Gygi SP, Chakrabarti D. 2013. Global analysis of protein
953 expression and phosphorylation of three stages of *plasmodium falciparum*
954 intraerythrocytic development. *J Proteome Res* 12:4028–4045.
- 955 38. Aurecochea C, Brestelli J, Brunk BP, Dommer J, Fischer S, Gajria B, Gao X, Gingle
956 A, Grant G, Harb OS, Heiges M, Innamorato F, Iodice J, Kissinger JC, Kraemer E, Li
957 W, Miller JA, Nayak V, Pennington C, Pinney DF, Roos DS, Ross C, Stoeckert CJ,
958 Treatman C, Wang H. 2009. PlasmoDB: a functional genomic database for malaria
959 parasites. *Nucleic Acids Res* 37:D539–D543.
- 960 39. Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O,
961 Tunyasuvunakool K, Bates R, Žídek A, Potapenko A, Bridgland A, Meyer C, Kohl
962 SAA, Ballard AJ, Cowie A, Romera-Paredes B, Nikolov S, Jain R, Adler J, Back T,
963 Petersen S, Reiman D, Clancy E, Zielinski M, Steinegger M, Pacholska M,
964 Berghammer T, Bodenstein S, Silver D, Vinyals O, Senior AW, Kavukcuoglu K, Kohli
965 P, Hassabis D. 2021. Highly accurate protein structure prediction with AlphaFold.
966 *Nature* 596:583–589.
- 967 40. Holm L. 2020. DALI and the persistence of protein shape. *Protein Sci* 29:128–140.

- 968 41. Birnbaum J, Flemming S, Reichard N, Soares AB, Mesén-Ramírez P, Jonscher E,
969 Bergmann B, Spielmann T. 2017. A genetic system to study Plasmodium falciparum
970 protein function. Nat Methods 14:450–456.
- 971 42. Prommana P, Uthapibull C, Wongsombat C, Kamchonwongpaisan S, Yuthavong Y,
972 Knuepfer E, Holder AA, Shaw PJ. 2013. Inducible Knockdown of Plasmodium Gene
973 Expression Using the glmS Ribozyme. PLoS One 8:e73783.
- 974 43. Tawk L, Chicanne G, Dubremetz J-F, Richard V, Payrastra B, Vial HJ, Roy C,
975 Wengelnik K. 2010. Phosphatidylinositol 3-Phosphate, an Essential Lipid in
976 Plasmodium, Localizes to the Food Vacuole Membrane and the Apicoplast. Eukaryot
977 Cell 9:1519–1530.
- 978 44. Jonscher E, Flemming S, Schmitt M, Sabitzki R, Reichard N, Birnbaum J, Bergmann
979 B, Höhn K, Spielmann T. 2019. PfVPS45 Is Required for Host Cell Cytosol Uptake by
980 Malaria Blood Stage Parasites. Cell Host Microbe 25:166-173.e5.
- 981 45. Waller RF, Reed MB, Cowman AF, McFadden GI. 2000. Protein trafficking to the
982 plastid of Plasmodium falciparum is via the secretory pathway. EMBO J 19:1794–
983 1802.
- 984 46. Birnbaum J, Scharf S, Schmidt S, Jonscher E, Hoeijmakers WAM, Flemming S,
985 Toenhake CG, Schmitt M, Sabitzki R, Bergmann B, Fröhlke U, Mesén-Ramírez P,
986 Blancke Soares A, Herrmann H, Bártfai R, Spielmann T. 2020. A Kelch13-defined
987 endocytosis pathway mediates artemisinin resistance in malaria parasites. Science
988 (80-) 367:51–59.
- 989 47. Inoue T, Heo W Do, Grimley JS, Wandless TJ, Meyer T. 2005. An inducible
990 translocation strategy to rapidly activate and inhibit small GTPase signaling pathways.
991 Nat Methods 2:415–418.
- 992 48. Geiger M, Brown C, Wichers JS, Strauss J, Lill A, Thuenauer R, Liffner B, Wilcke L,
993 Lemcke S, Heincke D, Pazicky S, Bachmann A, Löw C, Wilson DW, Filarsky M, Burda
994 P-C, Zhang K, Junop M, Gilberger TW. 2020. Structural Insights Into PfARO and
995 Characterization of its Interaction With PfAIP. J Mol Biol 432:878–896.
- 996 49. Cabrera A, Herrmann S, Warszta D, Santos JM, John Peter AT, Kono M, Debrouver
997 S, Jacobs T, Spielmann T, Ungermann C, Soldati-Favre D, Gilberger TW. 2012.
998 Dissection of Minimal Sequence Requirements for Rhoptry Membrane Targeting in the
999 Malaria Parasite. Traffic 13:1335–1350.
- 1000 50. Peterson MG, Marshall VM, Smythe JA, Crewther PE, Lew A, Silva A, Anders RF,

1001 Kemp DJ. 1989. Integral membrane protein located in the apical complex of
1002 *Plasmodium falciparum*. Mol Cell Biol 9:3151–3154.

1003 51. Wichers JS, Wunderlich J, Heincke D, Pazicky S, Strauss J, Schmitt M, Kimmel J,
1004 Wilcke L, Scharf S, von Thien H, Burda P, Spielmann T, Löw C, Filarsky M, Bachmann
1005 A, Gilberger TW. 2021. Identification of novel inner membrane complex and apical
1006 annuli proteins of the malaria parasite *Plasmodium falciparum*. Cell Microbiol
1007 23:e13341.

1008 52. Jullien N, Goddard I, Selmi-Ruby S, Fina J-L, Cremer H, Herman J-P. 2007.
1009 Conditional Transgenesis Using Dimerizable Cre (DiCre). PLoS One 2:e1355.

1010 53. Andenmatten N, Egarter S, Jackson AJ, Jullien N, Herman JP, Meissner M. 2013.
1011 Conditional genome engineering in *Toxoplasma gondii* uncovers alternative invasion
1012 mechanisms. Nat Methods 10:125–127.

1013 54. Holder AA, Lockyer MJ, Odink KG, Sandhu JS, Riveros-Moreno V, Nicholls SC,
1014 Hillman Y, Davey LS, Tizard MLV, Schwarz RT, Freeman RR. 1985. Primary structure
1015 of the precursor to the three major surface antigens of *Plasmodium falciparum*
1016 merozoites. Nature 317:270–273.

1017 55. Mesén-Ramírez P, Bergmann B, Tran TT, Garten M, Stäcker J, Naranjo-Prado I, Höhn
1018 K, Zimmerberg J, Spielmann T. 2019. EXP1 is critical for nutrient uptake across the
1019 parasitophorous vacuole membrane of malaria parasites. PLoS Biol 17:e3000473.

1020 56. López-Barragán MJ, Lemieux J, Quiñones M, Williamson KC, Molina-Cruz A, Cui K,
1021 Barillas-Mury C, Zhao K, Su X zhuan. 2011. Directional gene expression and
1022 antisense transcripts in sexual and asexual stages of *Plasmodium falciparum*. BMC
1023 Genomics 12:587.

1024 57. Lasonder E, Rijpma SR, Van Schaijk BCL, Hoeijmakers WAM, Kensche PR, Gresnigt
1025 MS, Italiaander A, Vos MW, Woestenenk R, Bousema T, Mair GR, Khan SM, Janse
1026 CJ, Bártfai R, Sauerwein RW. 2016. Integrated transcriptomic and proteomic analyses
1027 of *P. Falciparum* gametocytes: Molecular insight into sex-specific processes and
1028 translational repression. Nucleic Acids Res 44:6087–6101.

1029 58. Boltryk SD, Passecker A, Alder A, Carrington E, van de Vegte-Bolmer M, van Gemert
1030 G-J, van der Starre A, Beck H-P, Sauerwein RW, Kooij TWA, Brancucci NMB,
1031 Proellocks NI, Gilberger T-W, Voss TS. 2021. CRISPR/Cas9-engineered inducible
1032 gametocyte producer lines as a valuable tool for *Plasmodium falciparum* malaria
1033 transmission research. Nat Commun 12:4806.

- 1034 59. Filarsky M, Fraschka SA, Niederwieser I, Brancucci NMB, Carrington E, Carrió E,
1035 Moes S, Jenoe P, Bártfai R, Voss TS. 2018. GDV1 induces sexual commitment of
1036 malaria parasites by antagonizing HP1-dependent gene silencing. *Science* (80-)
1037 359:1259–1263.
- 1038 60. Ennist NM, Staybrook SE, Dutton PL, Moser CC. 2017. 5VJT: De Novo Photosynthetic
1039 Reaction Center Protein Equipped with Heme B and Zn(II) cations
1040 <https://doi.org/10.2210/pdb5VJT/pdb>.
- 1041 61. Wunderlich J, Rohrbach P, Dalton JP. 2012. The malaria digestive vacuole. *Front*
1042 *Biosci* (Schol Ed) 4:1424–48.
- 1043 62. Tabuchi M, Yoshimori T, Yamaguchi K, Yoshida T, Kishi F. 2000. Human
1044 NRAMP2/DMT1, which mediates iron transport across endosomal membranes, is
1045 localized to late endosomes and lysosomes in HEp-2 cells. *J Biol Chem* 275:22220–
1046 22228.
- 1047 63. Zhang M, Wang C, Otto TD, Oberstaller J, Liao X, Adapa SR, Udenze K, Bronner IF,
1048 Casandra D, Mayho M, Brown J, Li S, Swanson J, Rayner JC, Jiang RHY, Adams JH.
1049 2018. Uncovering the essential genes of the human malaria parasite *Plasmodium*
1050 *falciparum* by saturation mutagenesis. *Science* 360:eaap7847.
- 1051 64. Kennedy K, Cobbald SA, Hanssen E, Birnbaum J, Spillman NJ, McHugh E, Brown H,
1052 Tilley L, Spielmann T, McConville MJ, Ralph SA. 2019. Delayed death in the malaria
1053 parasite *Plasmodium falciparum* is caused by disruption of prenylation-dependent
1054 intracellular trafficking. *PLOS Biol* 17:e3000376.
- 1055 65. Pasaje CFA, Cheung V, Kennedy K, Lim EE, Baell JB, Griffin MDW, Ralph SA. 2016.
1056 Selective inhibition of apicoplast tryptophanyl-tRNA synthetase causes delayed death
1057 in *Plasmodium falciparum*. *Sci Rep* 6:1–13.
- 1058 66. Yeh E, DeRisi JL. 2011. Chemical rescue of malaria parasites lacking an apicoplast
1059 defines organelle function in blood-stage *plasmodium falciparum*. *PLoS Biol* 9.
- 1060 67. Bushell E, Gomes AR, Sanderson T, Anar B, Girling G, Herd C, Metcalf T,
1061 Modrzynska K, Schwach F, Martin RE, Mather MW, McFadden GI, Parts L, Rutledge
1062 GG, Vaidya AB, Wengelnik K, Rayner JC, Billker O. 2017. Functional Profiling of a
1063 *Plasmodium* Genome Reveals an Abundance of Essential Genes. *Cell* 170:260-
1064 272.e8.
- 1065 68. Chasen NM, Stasic AJ, Asady B, Coppens I, Moreno SNJ. 2019. The Vacuolar Zinc
1066 Transporter TgZnT Protects *Toxoplasma gondii* from Zinc Toxicity. *mSphere*

1067 4:e00086-19.

1068 69. Jiang Y, Wei J, Cui H, Liu C, Zhi Y, Jiang Z, Li Z, Li S, Yang Z, Wang X, Qian P,
1069 Zhang C, Zhong C, Su X, Yuan J. 2020. An intracellular membrane protein GEP1
1070 regulates xanthurenic acid induced gametogenesis of malaria parasites. *Nat Commun*
1071 11:1764.

1072 70. Sonnhammer EL, von Heijne G, Krogh A. 1998. A hidden Markov model for predicting
1073 transmembrane helices in protein sequences. *Proceedings Int Conf Intell Syst Mol Biol*
1074 6:175–82.

1075 71. Käll L, Krogh A, Sonnhammer ELL. 2004. A combined transmembrane topology and
1076 signal peptide prediction method. *J Mol Biol* 338:1027–1036.

1077 72. Liu W, Sundararaman SA, Loy DE, Learn GH, Li Y, Plenderleith LJ, Ndjango JBN,
1078 Speede S, Atencia R, Cox D, Shaw GM, Ayoub A, Peeters M, Rayner JC, Hahn BH,
1079 Sharp PM. 2016. Multigenomic delineation of Plasmodium species of the Laverania
1080 subgenus infecting wild-living chimpanzees and gorillas. *Genome Biol Evol* 8:1929–
1081 1939.

1082 73. Zanghi G, Vembar SS, Baumgarten S, Ding S, Guizetti J, Bryant JM, Mattei D, Jensen
1083 ATR, Rénia L, Goh YS, Sauerwein R, Hermsen CC, Franetich J-F, Bordessoulles M,
1084 Silvie O, Soulard V, Scatton O, Chen P, Mecheri S, Mazier D, Scherf A. 2018. A
1085 Specific PfEMP1 Is Expressed in *P. falciparum* Sporozoites and Plays a Role in
1086 Hepatocyte Infection. *Cell Rep* 22:2951–2963.

1087 74. Gómez-Díaz E, Yerbanga RS, Lefèvre T, Cohuet A, Rowley MJ, Ouedraogo JB,
1088 Corces VG. 2017. Epigenetic regulation of Plasmodium falciparum clonally variant
1089 gene expression during development in Anopheles gambiae. *Sci Rep* 7.

1090 75. Howick VM, Russell AJC, Andrews T, Heaton H, Reid AJ, Natarajan K, Butungi H,
1091 Metcalf T, Verzier LH, Rayner JC, Berriman M, Herren JK, Billker O, Hemberg M,
1092 Talman AM, Lawniczak MKN. 2019. The malaria cell atlas: Single parasite
1093 transcriptomes across the complete Plasmodium life cycle. *Science* (80-) 365.

1094 76. Burda P-C, Crosskey T, Lauk K, Zurborg A, Söhnchen C, Liffner B, Wilcke L, Strauss
1095 J, Jeffries CM, Svergun DI, Wilson DW, Wilmanns M, Gilberger T-W, Pietsch E,
1096 Strauss J, Jeffries CM, Svergun DI, Wilson DW, Wilmanns M, Gilberger T-W. 2020.
1097 Structure-Based Identification and Functional Characterization of a Lipocalin in the
1098 Malaria Parasite Plasmodium falciparum. *Cell Rep* 31:107817.

1099 77. Auburn S, Böhme U, Steinbiss S, Trimarsanto H, Hostetler J, Sanders M, Gao Q,

1100 Nosten F, Newbold CI, Berriman M, Price RN, Otto TD. 2016. A new *Plasmodium*
1101 *vivax* reference sequence with improved assembly of the subtelomeres reveals an
1102 abundance of *pir* genes. *Wellcome Open Res* 1:4.

1103 78. Pain A, Böhme U, Berry AE, Mungall K, Finn RD, Jackson AP, Mourier T, Mistry J,
1104 Pasini EM, Aslett MA, Balasubrammaniam S, Borgwardt K, Brooks K, Carret C, Carver
1105 TJ, Cherevach I, Chillingworth T, Clark TG, Galinski MR, Hall N, Harper D, Harris D,
1106 Hauser H, Ivens A, Janssen CS, Keane T, Larke N, Lapp S, Marti M, Moule S, Meyer
1107 IM, Ormond D, Peters N, Sanders M, Sanders S, Sargeant TJ, Simmonds M, Smith F,
1108 Squares R, Thurston S, Tivey AR, Walker D, White B, Zuiderwijk E, Churcher C, Quail
1109 MA, Cowman AF, Turner CMR, Rajandream MA, Kocken CHM, Thomas AW,
1110 Newbold CI, Barrell BG, Berriman M. 2008. The genome of the simian and human
1111 malaria parasite *Plasmodium knowlesi*. *Nature* 455:799–803.

1112 79. Trager W, Jensen JB. 1997. Continuous culture of *Plasmodium falciparum*: its impact
1113 on malaria research. *Int J Parasitol* 27:989–1006.

1114 80. Lambros C, Vanderberg JP. 1979. Synchronization of *Plasmodium falciparum*
1115 Erythrocytic Stages in Culture. *J Parasitol* 65:418.

1116 81. Ponnudurai T, Lensen AHW, Meis JFGM, Meuwissen JHE. 1986. Synchronization of
1117 *Plasmodium falciparum* gametocytes using an automated suspension culture system.
1118 *Parasitology* 93:263–274.

1119 82. Rivadeneira E, Wasserman M, Espinal C. 1983. Separation and Concentration of
1120 Schizonts of *Plasmodium falciparum* by Percoll Gradients. *J Protozool* 30:367–370.

1121 83. Moon RW, Hall J, Rangkuti F, Ho YS, Almond N, Mitchell GH, Pain A, Holder AA,
1122 Blackman MJ. 2013. Adaptation of the genetically tractable malaria pathogen
1123 *Plasmodium knowlesi* to continuous culture in human erythrocytes. *Proc Natl Acad Sci*
1124 110:531–536.

1125 84. Ganesan SM, Morrissey JM, Ke H, Painter HJ, Laroia K, Phillips MA, Rathod PK,
1126 Mather MW, Vaidya AB. 2011. Yeast dihydroorotate dehydrogenase as a new
1127 selectable marker for *Plasmodium falciparum* transfection. *Mol Biochem Parasitol*
1128 177:29–34.

1129 85. Grüning C, Spielmann T. 2012. Imaging of live malaria blood stage parasites. *Methods*
1130 *Enzymol* 506:81–92.

1131 86. Bachmann A, Scholz JAM, Janßen M, Klinkert M-Q, Tannich E, Bruchhaus I, Petter M.
1132 2015. A comparative study of the localization and membrane topology of members of

1133 the RIFIN, STEVOR and PfMC-2TM protein families in Plasmodium falciparum-
1134 infected erythrocytes. Malar J 14:274.

1135 87. Collins CR, Hackett F, Strath M, Penzo M, Withers-Martinez C, Baker DA, Blackman
1136 MJ. 2013. Malaria Parasite cGMP-dependent Protein Kinase Regulates Blood Stage
1137 Merozoite Secretory Organelle Discharge and Egress. PLoS Pathog 9:e1003344.

1138 88. Tonkin CJ, Van Dooren GG, Spurck TP, Struck NS, Good RT, Handman E, Cowman
1139 AF, McFadden GI. 2004. Localization of organellar proteins in Plasmodium falciparum
1140 using a novel set of transfection vectors and a new immunofluorescence fixation
1141 method. Mol Biochem Parasitol 137:13–21.

1142 89. Blackman MJ, Whittle H, Holder AA. 1991. Processing of the Plasmodium falciparum
1143 major merozoite surface protein-1: identification of a 33-kilodalton secondary
1144 processing product which is shed prior to erythrocyte invasion. Mol Biochem Parasitol
1145 49:35–44.

1146 90. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch
1147 S, Rueden C, Saalfeld S, Schmid B, Tinevez J-Y, White DJ, Hartenstein V, Eliceiri K,
1148 Tomancak P, Cardona A. 2012. Fiji: an open-source platform for biological-image
1149 analysis. Nat Methods 9:676–682.

1150 91. Mesén-Ramírez P, Reinsch F, Blancke Soares A, Bergmann B, Ullrich AK, Tenzer S,
1151 Spielmann T. 2016. Stable Translocation Intermediates Jam Global Protein Export in
1152 Plasmodium falciparum Parasites and Link the PTEX Component EXP2 with
1153 Translocation Activity. PLoS Pathog 12:e1005618.

1154 92. Struck NS, de Souza Dias S, Langer C, Marti M, Pearce JA, Cowman AF, Gilberger
1155 TW. 2005. Re-defining the Golgi complex in Plasmodium falciparum using the novel
1156 Golgi marker PfGRASP. J Cell Sci 118:5603–5613.

1157 93. Malleret B, Claser C, Ong ASM, Suwanarusk R, Sriprawat K, Howland SW, Russell B,
1158 Nosten F, Rénia L. 2011. A rapid and robust tri-color flow cytometry assay for
1159 monitoring malaria parasite development. Sci Rep 1:118.

1160 94. Wichers JS, van Gelder C, Fuchs G, Ruge JM, Pietsch E, Ferreira JL, Safavi S, von
1161 Thien H, Burda P-C, Mesén-Ramírez P, Spielmann T, Strauss J, Gilberger T-W,
1162 Bachmann A. 2021. Characterization of Apicomplexan Amino Acid Transporters
1163 (ApiATs) in the Malaria Parasite Plasmodium falciparum. mSphere 6.

1164 95. Galen SC, Borner J, Martinsen ES, Schaer J, Austin CC, West CJ, Perkins SL. 2018.
1165 The polyphyly of Plasmodium: Comprehensive phylogenetic analyses of the malaria

1166 parasites (Order Haemosporida) reveal widespread taxonomic conflict. R Soc Open
1167 Sci 5.

1168 96. Yu G, Smith DK, Zhu H, Guan Y, Lam TT-Y. 2017. ggtree: an r package for
1169 visualization and annotation of phylogenetic trees with their covariates and other
1170 associated data. Methods Ecol Evol 8:28–36.

1171 97. Yu G. 2020. Using ggtree to Visualize Data on Tree-Like Structures. Curr Protoc
1172 Bioinforma 69:e96.

1173 98. Katoh K, Standley DM. 2013. MAFFT Multiple Sequence Alignment Software Version
1174 7: Improvements in Performance and Usability. Mol Biol Evol 30:772–780.

1175 99. Madeira F, Park YM, Lee J, Buso N, Gur T, Madhusoodanan N, Basutkar P, Tivey
1176 ARN, Potter SC, Finn RD, Lopez R. 2019. The EMBL-EBI search and sequence
1177 analysis tools APIs in 2019. Nucleic Acids Res 47:W636–W641.

1178 100. Davis MW, Jorgensen EM. 2022. ApE, A Plasmid Editor: A Freely Available DNA
1179 Manipulation and Visualization Program. Front Bioinforma 2:5.

1180 101. Lord SJ, Velle KB, Mullins RD, Fritz-Laylin LK. 2020. SuperPlots: Communicating
1181 reproducibility and variability in cell biology. J Cell Biol 219.

1182 102. Tibúrcio M, Hitz E, Niederwieser I, Kelly G, Davies H, Doerig C, Billker O, Voss TS,
1183 Treeck M. 2021. A 39-Amino-Acid C-Terminal Truncation of GDV1 Disrupts Sexual
1184 Commitment in Plasmodium falciparum. mSphere 6.

1185 103. Eksi S, Morahan BJ, Haile Y, Furuya T, Jiang H, Ali O, Xu H, Kiattibutr K, Suri A,
1186 Czesny B, Adeyemo A, Myers TG, Sattabongkot J, Su X zhuan, Williamson KC. 2012.
1187 Plasmodium falciparum Gametocyte Development 1 (Pfgdv1) and Gametocytogenesis
1188 Early Gene Identification and Commitment to Sexual Development. PLoS Pathog 8.

1189




Figure 2




Figure 3






Figure 4


A




B




C




D




E




F







A




B



C



D



E

